873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models

• Man Zhang,
• Jin Liu,
• Celia Chen,
• Xin Cheng,
• Feng Ren,
• Jianyu Wu,
• Luoheng Qin,
• Supriya Bavadekar,
• Sujata Rao,
• Alex Zhavoronkov

Affiliations

Man Zhang

Department of Hematology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, China

Jin Liu

1Insilico Medicine, Shanghai, China

Celia Chen

1Insilico Medicine, Shanghai, China

Xin Cheng

1Insilico Medicine, Shanghai, China

Feng Ren

1Insilico Medicine, Shanghai, China

Jianyu Wu

1Insilico Medicine, Shanghai, China

Luoheng Qin

1Insilico Medicine, Shanghai, China

Supriya Bavadekar

2Insilico Medicine, New York, NY, USA

Sujata Rao

2Insilico Medicine, New York, NY, USA

Alex Zhavoronkov

1Insilico Medicine, Shanghai, China